Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on symptoms of vulvovaginal atrophy due to menopause and to collect further data on subjects exposed to intravaginal DHEA in order to meet the ICH E1 guideline requirements.

date/time interval

  • February 1, 2014 - February 1, 2015